Pipeline / Targeted Indication / Pulmonary Hypertension (PH) WHO Group 3

INCREASE - Phase 3 clinical trial with Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatments of pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Phase 3 clinical trial with Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).